Related Experiment Video

Updated: Jan 21, 2026

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.6K

Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?

Shahin Aghamiri1, Keyvan Fallah Mehrjardi2,3, Sasan Shabani4

  • 1Student Research Committee, Department of Medical Biotechnology, School of Advanced Technology in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, 19839-63113, Iran.

Nanomedicine (London, England)
|August 2, 2019
PubMed

Insights

Nanoparticle-delivered siRNA offers a promising solution to overcome chemotherapy resistance and side effects in ovarian cancer treatment. This review explores advanced nanoparticle strategies for targeted gene silencing and drug delivery.

Area of Science:

  • Oncology
  • Nanotechnology
  • Pharmacology

Background:

  • Ovarian cancer remains a leading cause of cancer mortality globally.
  • Chemotherapy often fails in advanced stages due to multidrug resistance (MDR) and severe side effects from nonspecific toxicity.
  • RNA interference (RNAi) using small interfering RNA (siRNA) presents a strategy for targeted gene silencing.

Purpose of the Study:

  • To review current advances in nanoparticle-mediated siRNA delivery systems for ovarian cancer therapy.
  • To discuss strategies for overcoming chemotherapy limitations using targeted gene silencing.
  • To highlight nanoparticle-based codelivery of anticancer drugs and siRNA as a novel therapeutic approach.

Main Methods:

  • Review of existing literature on nanoparticle-mediated siRNA delivery.
  • Categorization of delivery systems including polymeric-, lipid-based, and rigid nanoparticles.
  • Discussion of ligand-coupled nanoparticles for targeted delivery.
  • Exploration of codelivery strategies for combined chemo- and gene therapy.

Main Results:

  • Nanoparticle-based siRNA delivery enables specific silencing of oncogenes and MDR-associated genes.
  • Various nanoparticle platforms show potential for efficient siRNA delivery in ovarian cancer models.
  • Codelivery systems offer a synergistic approach to combatting MDR and enhancing therapeutic efficacy.

Conclusions:

  • Nanoparticle-mediated siRNA delivery is a promising strategy to address limitations of conventional chemotherapy in ovarian cancer.
  • Targeted delivery and codelivery systems represent cutting-edge approaches for advanced ovarian cancer treatment.
  • Further research into these nanomedicine strategies could lead to improved patient outcomes.
Keywords:
RNA interferencecodelivery systemhyperthermia therapyimaginglipid-based deliverynanoparticleovarian cancerphotodynamic therapypolymeric-based siRNA deliverysiRNA delivery systems

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

7.9K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

4.3K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K
Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
3.5K